FULC Q4 2022 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$685,000-86.5% YoY

Gross Profit

-$18M-2610.4% margin

Operating Income

-$28M-4083.6% margin

Net Income

-$26M-3815.3% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

-42.1%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$227M

Total Liabilities

$28M

Stockholders' Equity

$199M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$685,000	$5M	-86.5%
Gross Profit	-$18M	-$14M	-29.1%
Operating Income	-$28M	-$24M	-18.7%
Net Income	-$26M	-$23M	-11.3%